Opinion|Videos|December 18, 2024

Overview of KOMET-007: Ziftomenib Use in NPM-1m or KMT2A-r AML

With the Oncology Brothers, Uma Borate, MD, discusses how ziftomenib is showing promising results as a targeted therapy for NPM1-mutated and KMT2A-rearranged acute myeloid leukemia (AML) in the ongoing KOMET-007 trial, offering potential new treatment options for this challenging patient population.


Latest CME